-
【Press Release】Metagen Therapeutics Raises JPY 1.1B in Initial Closing of Series A
Yamagata, Japan – Metagen Therapeutics (President and CEO: Taku Nakahara, PhD; Headquarters: Yamagata, Japan; […] -
【Press Release】Antibiotic Fecal Microbiota Transplantation for Ulcerative Colitis Patients Approved Under Japan’s Advanced Medical Care Program
January 4, 2023 JAPAN – Juntendo University (Bunkyo-ku, Tokyo, President: Hajime Arai) and Metagen Therapeutic […] -
【Press Release】 Metagen Therapeutics Raises 140M JPY in Pre-Series A For Its Microbiome Drug Discovery
10.06.2022 Yamagata, Japan—Metagen Therapeutics Inc. (President and CEO: Taku Nakahara; Headquarters: Yamagata […] -
【Press Release】Metagen Therapeutics and Juntendo University Establish a Joint Research Course, the ‘Microbiome Regeneration Course’
April 12, 2022 Yamagata, Japan—Metagen Therapeutics Inc. (President and CEO: Taku Nakahara; Headquarters: Yama […] -
【Press Release】Metagen Therapeutics, Inc. Joins Juntendo University In AMED’s ‘Project Focused on Developing Key Technology for Discovering and Manufacturing Drugs for Next-Generation Treatment and Diagnosis’ (Development of Next-Generation Drug Discovery Technology by Controlling Intestinal Microbiome)”
Promoting inflammatory bowel disease (IBD) seeds creation research with Juntendo University October 12, 2021 Y […] -
【Press Release】Metagen Therapeutics Raises Seed Round Funding of 90M JPY
March 17, 2021 Yamagata, Japan—Metagen Therapeutics Inc. (President and CEO: Taku Nakahara; Headquarters: Yama […]